Company Overview of Aurobindo Pharma USA Inc.
Aurobindo Pharma USA Inc. manufactures generic pharmaceutical drugs. The company was incorporated in 2004 and is based in Dayton, New Jersey. Aurobindo Pharma USA Inc. operates as a subsidiary of Aurobindo Pharma Ltd.
6, Wheeling Road
Dayton, NJ 08810
Founded in 2004
Key Executives for Aurobindo Pharma USA Inc.
Compensation as of Fiscal Year 2014.
Aurobindo Pharma USA Inc. Key Developments
Bristol-Myers Drags Aurobindo and Aurobindo Pharma USA Inc. to US Court
Jun 10 14
Bristol-Myers Squibb has dragged Aurobindo and its Aurobindo Pharma USA Inc. to the US District Court of New Jersey for alleged patent infringement of its anti-HIV drug 'Reyataz'. In its plea, BMS said legal action has been initiated against Aurobindo for infringement of patent no. 6,087,383 and asked the local American court to with hold approval to manufacture and market a generic version of BMS's Reyataz before the expiration of its patent on December 21, 2018. Bristol-Myers Squibb legal action follows an Abbreviated New Drug Application (ANDA) No 204806 filed by Aurobindo Pharma Ltd. with the US Food and Drug Administration (USFDA) for approval to manufacture and market a generic version of BMS's Reyataz drug product. BMS had clocked sales of $394 million from Reyataz in its fourth quarter ended December 31, 2014. Seeking relief from the US court, BMS stated that damages or other monetary relief must be granted to the company if Aurobindo engages in the commercial manufacture, use, sale of its generic product prior to expiration of the '383 patent. BMS further added that it will be irreparably harmed if Aurobindo's infringement is not enjoined by the court.
Aurobindo Pharma USA Inc. Announces Board Changes
Aug 27 12
Aurobindo Pharma Ltd. has announced that the board of directors of the company at its meeting held on August 25, 2012, have approved the proposal of appointment of Mr. P. V. Ramprasad Reddy as Executive Chairman of Aurobindo Pharma USA Inc., the wholly owned subsidiary of the company with effect from December 01, 2012. The said proposal is subject to further approval of the shareholders of the company. Accordingly, an Extra Ordinary General Meeting of the company is being convened on September 27, 2012. Consequent to his proposed appointment in the company's US subsidiary, the Board has also approved Mr. Ramprasad Reddy relinquishing the executive responsibilities as Wholetime Director of the company and his continuation as a Non-Executive Director of the company not liable to retire by rotation with effect from December 01, 2012.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries